-
Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;35:249-57. pdf -
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia.
Parra MC, Lees C, Mann GE, Pearson JD, Nicolaides KH.
Am J Obstet Gynecol 2001;184:497-502. -
Repeatability of measurement of uterine artery pulsatility index using transvaginal color Doppler.
Papageorghiou AT, To MS, Yu CK, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:456-9. -
Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation.
Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:441-9. -
First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction.
Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH.
Obstet Gynecol 2001;98:608-11. -
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation.
Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:583-6. -
Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks.
Lees C, Parra M, Missfelder-Lobos H, Morgans A, Fletcher O, Nicolaides KH.
Obstet Gynecol 2001;98:369-73.